STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #1942 by analyst upside · 2026-06-27
SRPT
Sarepta Therapeutics, Inc.
Healthcare · Market Cap $2B · P/E 45.5x
ANALYST PRICE TARGET
+30.6%
implied upside to consensus target
Current Price $16.85
Consensus Target $22.0
Bull Target $38.0
Bear Target $5.0
Analysts Covering 23
ANALYST CONSENSUS - HOLD
Strong Buy
0
Buy
6
Hold
12
Sell
5
52-Week Low $10.42
52-Week High $25.32
YTD Return -20.9%
FUNDAMENTALS
Market Cap $2B
P/E Ratio (TTM) 45.5x
Forward P/E 6.2x
EPS (TTM) $0.37
PEG Ratio -0.09
Dividend Yield N/A
Revenue (TTM) $2.2B
Profit Margin 3.0%
52-WEEK RANGE
52-Week Low $10.42
52-Week High $25.32
Current Price $16.85
Bear Target $5.0
Bull Target $38.0
● Now $16.85 ● Target $22.0
TRADING DATA
Avg Volume 2.9M
YTD Return -20.9%
Analyst Count 23
Consensus Hold
Upside to Target +30.6%
Last Updated 2026-06-27

ANALYST SUMMARY

Sarepta Therapeutics, Inc. (SRPT) is currently trading at $16.85 with a Wall Street consensus price target of $22.0, implying potential upside of 30.6% over the next 12 months. 23 analysts currently cover SRPT, with a consensus rating of Hold - 26% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $38.0, while the most cautious has a target of $5.0.

SRPT operates in the Healthcare sector with a market capitalisation of $2B. The stock is down 20.9% year-to-date and is currently trading near the lower end of its 52-week range of $10.42 – $25.32.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

RECENT ANALYST CALLS

Upgrade/downgrade history for SRPT, with each firm's 90-day track record across all stocks we track. See full firm rankings →

HC Wainwright & Co. reit
Sell → Sell 2026-04-16 31% win rate (48 calls)
Citigroup — Reiterated
Sell → Sell 2026-03-26 Building track record
Needham reit
Underperform → Underperform 2026-03-26 20% win rate (5 calls)
Oppenheimer reit
Outperform → Outperform 2026-03-19 14% win rate (7 calls)
Mizuho — Reiterated
Outperform → Outperform 2026-03-13 Building track record
Citigroup — Reiterated
Sell → Sell 2026-03-10 Building track record
HC Wainwright & Co. reit
Sell → Sell 2026-03-02 31% win rate (48 calls)
Wells Fargo — Reiterated
Overweight → Overweight 2026-02-27 Building track record
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
26
out of 100
Coverage depth
24/30
Consensus clarity
0/30
Vote unanimity
0/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →